Cystic Fibrosis Weekly Update

Contents:

A Giant Win After a Big Loss

Aug 14, 2020 09:00 am | Lara Govendo

After a monstrous letdown, we need a win. Those of us with chronic illness need reminders to keep on keeping on. The glimmer of hope for better days is necessary to move forward. Rarely do we have a whole day that is good, so when we do, we cling to it with bated breath. Thursday […]
The post A Giant Win After a Big Loss appeared first on Cystic Fibrosis News Today.

MS1819-PERT Combo Shows Benefits for CF Patients With EPI in Phase 2 Trial

Aug 14, 2020 07:00 am | Joana Carvalho, PhD

MS1819, AzurRx BioPharma’s investigational treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF), safely increased fat absorption in the first five patients receiving the therapy alongside pancreatic enzyme replacement therapy (PERT) in a Phase 2 clinical trial. The interim analysis also showed the combination therapy led to clinically meaningful improvements in patients’ body […]
The post MS1819-PERT Combo Shows Benefits for CF Patients With EPI in Phase 2 Trial appeared first on Cystic Fibrosis News Today.

First Participants Dosed in Early Clinical Trial of Inhaled Therapy ARO-ENaC

Aug 13, 2020 07:00 am | Ines Martins, PhD

A Phase 1/2 clinical trial assessing Arrowhead Pharmaceuticals‘ investigational inhaled therapy, ARO-ENaC, for the treatment of cystic fibrosis (CF), has dosed its first participants, the company announced. The AROENaC1001 trial (NCT04375514) is designed to investigate ARO-ENaC in 24 healthy volunteers and 30 CF patients, and is currently recruiting participants. In healthy people the goal is to […]
The post First Participants Dosed in Early Clinical Trial of Inhaled Therapy ARO-ENaC appeared first on Cystic Fibrosis News Today.